FOXD1 expression-based prognostic model for uveal melanoma

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Forkhead box D1 (FOXD1) is a transcription factor involved in cell reprogramming.
• The role of FOXD1 in the prognosis of uveal melanoma (UVM) remains largely unknown.
• Understanding FOXD1's contribution is crucial for improving UVM patient outcomes.

Purpose of the Study:

• To investigate the prognostic significance of FOXD1 in uveal melanoma.
• To elucidate the underlying biological mechanisms of FOXD1 in UVM.
• To develop a novel prognostic model for UVM patients based on FOXD1.

Main Methods:

• Analysis of FOXD1 expression correlation with patient survival data (overall, progression-free, and disease-specific survival).
• In vitro experiments using the human uveal melanoma cell line MUM2B.
• Bioinformatic analysis of The Cancer Genome Atlas (TCGA) database for FOXD1-related genomic spectrum, pathways, tumor microenvironment, and drug sensitivity.

Main Results:

• FOXD1 expression was negatively correlated with overall survival, progression-free survival, and disease-specific survival in UVM patients, suggesting a role in promoting tumor growth and invasion.
• Experimental verification in the MUM2B cell line supported the pro-tumorigenic role of FOXD1.
• A novel prognostic model was developed using FOXD1-related immunomodulators (TMEM173, TNFRSF4, TNFSF13, ULBP1) for disease stratification.

Conclusions:

• FOXD1 is a potential oncoprotein that promotes tumor growth and invasion in uveal melanoma.
• FOXD1 expression serves as a negative prognostic biomarker for UVM.
• The developed prognostic model offers a new tool for stratifying UVM patients and guiding clinical treatment strategies.